Navigation Links
Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
Date:9/5/2012

option."

"Sym004 further strengthens our early development pipeline by adding a product that is thought to act via a proposed synergistic mechanism of action not previously studied, but more specifically, it has the potential to become a key asset complementing our already highly successful Erbitux franchise," commented Dr. Susan Jane Herbert, Head of Global Business Development and Strategy for Merck Serono. "This collaboration once again reflects our strong commitment to fighting cancer and to providing new treatment options to patients."

Sym004 is comprised of two antibodies that are not only designed to block ligand binding, receptor activation and downstream signaling but are also thought to elicit removal of the EGFR receptors from the cancer cell surface by inducing EGFR internalization and degradation.[1]

As of July 2012, 88 patients have been treated with Sym004 in clinical trials. The adverse events from the preliminary clinical data include diarrhea, skin rash, mucosal inflammation, nausea, infusion-related reaction and hypomagnesemia. Exposure data from the patients, after weekly repeated infusions, do not indicate an anti-drug antibody response.

References

1. Pedersen MW, et al. Cancer Res 2010;70:588-97.

Conference Call

Symphogen will host a conference call today (Thursday 6 September 2012) to discuss the announcement at 11:30 CET/ 10:30 BST.

Kirsten Drejer, Symphogen's Chief Executive Officer, will host the call to discuss the licence agreement with Merck KGaA for Sym004, followed by a Q&A session. The call will be conducted in English.  Please use the following dial-in details:

Denmark: 327-276-25

International: +44(0)1452-555-566

Please quote the following Conference ID: 28172177

An accompanying presentation will be released on Symphogen's website and available for download just before the start of the call and can be
'/>"/>

SOURCE Symphogen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
2. USPTO Grants Butamax a Further KARI Enzyme Patent
3. Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
4. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
5. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
6. NSF CAREER grants support ocean energy, microforming, computer planning
7. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
8. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
9. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
10. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
11. MO BIO Laboratories, Inc. Becomes Exclusive Sponsor Of Natures Human Microbiota Special
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Chips that use light, rather than electricity, to ... and energy efficiency is a growing concern as ... chief components of optical circuits light emitters, ... to build. One promising light source for optical ... optical properties when deposited as a single, atom-thick ...
(Date:9/19/2014)... , September 19, 2014 ... technology, development of emerging drug systems and advanced Laboratory ... Dickinson and Company (NYSE: BDX ), Thermo ... Biosciences Inc. (NASDAQ: RGDO ), Sangamo Biosciences ... (NASDAQ: HOLX) Pressure BioSciences, Inc. (OTCQB: PBIO) ...
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... DUBLIN , September 19, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the ... Pre-packed Chromatography Columns"  report to their offering.  ... columns market is one of the fastest-growing segments ... at $1.2 billion in 2013, and expected to ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... of online usability challenged businesses to better meet the ... Wednesday at a Web usability conference titled Are Your ... conference, which was hosted by the Madison chapter ... topics ranging from e-course standards to designing Web pages ...
... choice! , ,So what does government have to do ... -- I meant governance ! Theres ... that government caused governance or, at least, the recent emphasis on ... -- Enron, Worldcom, Tyco -- have reduced the publics trust in ...
... Wis. startups, biotech , ,Entrepreneurship, nanotechnology and biomedical ... 1-4 in Madison and Milwaukee, giving substance to what ... Week. , , Tips for Entrepreneurs , ,Established ... Wisconsin Entrepreneurs Conference , which runs June 1-2 at ...
Cached Biology Technology:Special needs addressed at Web Usability Conference 2Part 4 Project Performance Get on the path to continuous improvement 2Part 4 Project Performance Get on the path to continuous improvement 3Doyles Entrepreneurs and Research week nears 2Doyles Entrepreneurs and Research week nears 3
(Date:9/18/2014)... 18, 2014 New research into the Crimean-Congo hemorrhagic ... severe hemorrhagic disease in humans similar to that caused ... CCHFV infection. This discovery has the potential to lead ... , The research, reported in a paper ... and conducted by scientists at the Texas Biomedical Research ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, ... communicating creatures. , But by using a ... radically alter their behavior to suit their population. ... them are present, and act accordingly. , Once ... it may change from innocuous to pathogenic, or ...
(Date:9/18/2014)... researchers and their colleagues have built the first ... academic performance and behavioral trends. In other words, ... even if you don,t -- and how that ... students, happiness, stress, depression and loneliness to their ... general population for example, to monitor mental ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
... for colorectal cancer was reported today (Thursday, Oct. 24) ... in Boston. The interaction may shed light on the ... associated with consumption of red and processed meat, the ... relevant public health significance because diet is a modifiable ...
... operating principles of a genetic switch that cancer cells use ... the body. The study found that the on-off switch,s dynamics ... and "off." The extra setting both explains previously confusing experimental ... treatment. The study appears online this week in the ...
... breast cancer from families severely affected with the disease have ... vast majority of those patients were told that their gene ... genomics sequencing tools, the discovery of additional genes implicated in ... genetic testing for BRCA1 and BRCA2, it is now possible ...
Cached Biology News:Gene-diet interaction may help explain link between eating meat & colorectal cancer risk 2Gene-diet interaction may help explain link between eating meat & colorectal cancer risk 3Physicists decode decision circuit of cancer metastasis 2Physicists decode decision circuit of cancer metastasis 3Physicists decode decision circuit of cancer metastasis 4BROCA sequencing approach evaluates all 24 genes implicated in breast cancer 2BROCA sequencing approach evaluates all 24 genes implicated in breast cancer 3
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
... Mouse monoclonal antibody raised against a partial recombinant IFNA2. ... a.a.-188 a.a.) partial recombinant protein is produced in ... 10 8 IU/ mg. OMIM: ... Lot Number: MM951100564 ...
Biology Products: